Format

Send to

Choose Destination
Br J Cancer. 2018 May;118(9):1176-1178. doi: 10.1038/s41416-018-0061-6. Epub 2018 Mar 26.

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.

Author information

1
Memorial Sloan Kettering Cancer Center, New York, NY, 10075, USA. motzerr@MSKCC.ORG.
2
Institut Gustave Roussy, Villejuif, 94805, France.
3
Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK.
4
Exelixis, Inc, South San Francisco, CA, 94080, USA.
5
Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

Abstract

BACKGROUND:

In the phase 3 METEOR trial (NCT01865747), cabozantinib significantly improved progression-free survival, overall survival, and objective response rate compared with everolimus in patients with advanced renal cell carcinoma (RCC) after prior antiangiogenic therapy. A statistically significant improvement in overall survival was observed at a second interim analysis with 320 recorded deaths.

METHODS:

658 patients with advanced RCC who had received at least one prior VEGFR tyrosine kinase inhibitor were randomised 1:1 to cabozantinib (60 mg daily) or everolimus (10 mg daily). Survival follow-up continued to reach the 408 deaths that were pre-specified for the final analysis.

RESULTS:

With 430 deaths (198 for cabozantinib and 232 for everolimus), median overall survival was 21.4 months with cabozantinib and 17.1 months with everolimus (HR 0.70, 95% CI 0.58-0.85; P = 0.0002). Safety profiles of cabozantinib and everolimus were consistent with those reported previously.

CONCLUSIONS:

Cabozantinib significantly improved overall survival compared with everolimus in previously treated patients with advanced RCC with consistent results after long-term follow-up.

PMID:
29576624
PMCID:
PMC5943250
DOI:
10.1038/s41416-018-0061-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center